Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

12 results
Display

Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 2 and 3

Jung YK

Ever since direct-acting antiviral agents (DAA) have been approved and released into the world, numerous studies on the efficacy, adverse effects and drug-drug interactions of interferon-free DAA combination therapy have...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 1

Park SH

The introduction of direct-acting antiviral agents (DAAs) has markedly improved the sustained virological response (SVR) rates in patients with chronic hepatitis C. Currently, four classes of DAAs targeting three HCV...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prevalence, Risk Factors and Clinical Characteristics in Patients with Genotype 6 Chronic Hepatitis C: A Single Institute Experience

Shin SK, Park SY, Jung YK, Kim EJ, Lee HN, Lee JJ, Kwon OS, Choi DJ, Kim YS, Kim JH

BACKGROUND/AIMS: Hepatitis C genotypes 1 and 2 are widely distributed globally. In contrast, genotype 6 is found mainly in Southeast Asia, while genotype 6 is rare in Korea. This study...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Mutations within the interferon sensitivity determining region in Korean patients infected with hepatitis C virus genotype 1b

Jin YJ, Park YK, Yun GJ, Lee HC, Jeong SH, Kim GM, Lim YS, Chung YH, Lee YS, Suh DJ

BACKGROUND/AIMS: The treatment response to interferon could differ with mutations in the interferon-sensitivity-determining region (ISDR) in patients infected with hepatitis C virus (HCV) genotype-1b (HCV-Ib). We examined the pattern of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Predictors of spontaneous viral clearance and outcomes of acute hepatitis C infection

Cho YK, Kim YN, Song BC

BACKGROUND/AIMS: This study evaluated the predictors of spontaneous viral clearance (SVC), as defined by two consecutive undetectable hepatitis C virus (HCV) RNA tests performed > or =12 weeks apart, and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prevalence of Hepatitis C Virus Infections and Distribution of Hepatitis C Virus Genotypes among Korean Blood Donors

Oh DJ, Park YM, Seo YI, Lee JS, Lee JY

BACKGROUND: Hepatitis C virus (HCV) remains a worldwide health-care burden. Prevalence rates vary and the distribution of genotypes depends on geographical location. Here, the recent prevalence of HCV infections and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
24 Weeks Treatment with Pegylated Interferon Alfa Plus Ribavirin May Be Possible in Genotype 1 Chronic Hepatitis C Patients with Rapid Virological Response Who Have Low Pretreatment Viremia

Moon SS, Kang HG, Seo JA, Jung EU, Lee SH, Park SJ, Lee YJ, Seol SY

BACKGROUND/AIMS: The standard treatment for chronic hepatitis C infected with hepatitis C virus (HCV) genotype 1 is a combination of pegylated interferon alfa and ribavirin over a 48 weeks period....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C

Kim MN, Kim HS, Kim JK, Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Han KH

Hepatitis C virus core antigen (HCV Ag) is a recently developed marker of hepatitis C virus (HCV) infection. We investigated the clinical utility of the new HCV Ag assay for...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis

Kim KH, Jang BK, Chung WJ, Hwang JS, Kweon YO, Tak WY, Lee HJ, Lee CH, Suh JI

BACKGROUND/AIMS: Pegylated interferon (peginterferon) and ribavirin combination therapy is less effective and associated with a higher frequency of serious complications in chronic hepatitis C patients with cirrhosis than in noncirrhotic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical and epidemiological characteristics of Korean patients with hepatitis C virus genotype 6

Seong MH, Kil H, Kim JY, Lee SS, Jang ES, Kim JW, Jeong SH, Kim YS, Bae SH, Lee YJ, Lee HC, Yun H, Kang BH, Kim K

BACKGROUND/AIMS: The distribution of hepatitis C virus (HCV) genotypes varies geographically. In Korea, genotypes 1 and 2 comprise more than 90% of HCV infections, while genotype 6 is very rare....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection

Nam HC, Lee HL, Yang H, Song MJ

BACKGROUND/AIMS: The treatment strategy for hepatitis C virus (HCV) has been changing rapidly since the introduction of direct-acting antivirals such as daclatasvir (DCV) and asunaprevir (ASV). We evaluated the efficacy...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Characteristics and Treatment Outcome of Peginterferon Plus Ribavirin in Patients Infected with Genotype 6 Hepatitis C Virus in Korea: A Multicenter Study

Shin SR, Kim YS, Lim YS, Lee JS, Lee JW, Kim SM, Jeong SH, Sohn JH, Lee MS, Park SH

BACKGROUND/AIMS: Because of the limited geographic distribution, there have been insufficient data regarding hepatitis C virus (HCV) genotype 6 in Korea. This study aimed to investigate the clinical characteristics and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr